EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in glioblastoma

Sara Hiller-Vallina, Lucia Mondejar-Ruescas, Marta Caamaño-Moreno, Blanca Cómitre-Mariano, Denisse Alcivar-López, Juan M Sepulveda, Aurelio Hernández-Laín, Ángel Pérez-Núñez, Berta Segura-Collar iD, Ricardo Gargini iD

Neuro-Oncology · 05.07.2024 · 26 (7) · 1213-1227

DOI: 10.1093/neuonc/noae033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 27.02.2024. Verfasst von Sara Hiller-Vallina und 9 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigación Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid, Spain. Hauptthemen laut MEDLINE: Bevacizumab, Glioblastoma, Brain Neoplasms, Necrosis. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) is a highly malignant brain tumor that affects men more often than women. In addition, the former shows a poorer survival prognosis. To date, the reason for this sex-specific aggressiveness remains unclear. Therefore, the aim of this study is to investigate tumor processes that explain these sex differences.

Methods

This was a retrospective study of GBM patients which was stratified according to sex. A cohort with 73 tumors was analyzed with immunohistochemistry, RNA-seq and RT–qPCR to characterize differences in vascular and immunological profiles. Transcriptomic profiling, gene set enrichment analysis, and pathway enrichment analysis were used for discovering molecular pathways predominant in each group. We further investigated the therapeutic effect of bevacizumab (vascular endothelial growth factor A (VEGFA) blocking antibody) in a retrospective GBM cohort (36 tumors) based on sex differences.

Results

We found that under hypoxic tumor conditions, 2 distinct tumor immuno-angiogenic ecosystems develop linked to sex differences and ESR1 expression is generated. One of these subgroups, which includes male patients with low ESR1 expression, is characterized by vascular fragility associated with the appearance of regions of necrosis and high inflammation (called necroinflamed tumors). This male-specific tumor subtype shows high inflammation related to myeloid-derived suppressor cells infiltration. Using this stratification, we identified a possible group of patients who could respond to bevacizumab (BVZ) and revealed a genetic signature that may find clinical applications as a predictor of those who may benefit most from this treatment.

Conclusions

This study provides a stratification based on the sexual differences in GBM, which associates the poor prognosis with the presence of immunosuppressive myeloid cells in the necrotic areas. This new stratification could change the current prognosis of GBM and identifies those who respond to BVZ treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabGlioblastomaBrain NeoplasmsNecrosisHumansMaleFemaleRetrospective StudiesPrognosisMiddle AgedAntineoplastic Agents, ImmunologicalInflammationAgedAdultAngiogenesis InhibitorsBiomarkers, TumorFollow-Up StudiesSex CharacteristicsSurvival Rate

Stichwörter der Autor:innen

bevacizumabestrogen receptorglioblastomanecroinflammationsex differences

Substanzen

BevacizumabAntineoplastic Agents, ImmunologicalAngiogenesis InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Instituto de Investigación Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Pathology and Neurooncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Department of Neurosurgery, 12 de Octubre University Hospital (i+12), Madrid, Spain.

ORCID-Profile: Berta Segura-Collar, Ricardo Gargini

Förderung

  • Instituto de Salud Carlos III
  • European Union

Zitieren

APA

Hiller-Vallina, S., Mondejar-Ruescas, L., Caamaño-Moreno, M., Cómitre-Mariano, B., Alcivar-López, D., Sepulveda, J. M., Hernández-Laín, A., Pérez-Núñez, Á., Segura-Collar, B., & Gargini, R. (2024). Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in glioblastoma. Neuro-Oncology, 26(7), 1213-1227. https://doi.org/10.1093/neuonc/noae033

Vancouver

Hiller-Vallina S, Mondejar-Ruescas L, Caamaño-Moreno M, Cómitre-Mariano B, Alcivar-López D, Sepulveda JM, et al. Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in glioblastoma. Neuro-Oncology. 2024;26(7):1213-1227. doi:10.1093/neuonc/noae033

BibTeX
@article{HillerVallina2024,
  author = {Hiller-Vallina, Sara and Mondejar-Ruescas, Lucia and Caamaño-Moreno, Marta and Cómitre-Mariano, Blanca and Alcivar-López, Denisse and Sepulveda, Juan M and Hernández-Laín, Aurelio and Pérez-Núñez, Ángel and Segura-Collar, Berta and Gargini, Ricardo},
  title = {Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in glioblastoma},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {7},
  pages = {1213--1227},
  doi = {10.1093/neuonc/noae033}
}
Kostenlos starten →